Abstract
Bax inhibitor-1 (BI-1) is an evolutionarily-conserved endoplasmic reticulum protein. The expression of BI-1 in mammalian cells suppresses apoptosis induced by Bax, a pro-apoptotic member of the Bcl-2 family. BI-1 has been shown to be associated with calcium (Ca2+) levels, reactive oxygen species (ROS) production, cytosolic acidification, and autophagy as well as endoplasmic reticulum stress signaling pathways. According to both in vitro and clinical studies, BI-1 promotes the characteristics of cancers. In other diseases, BI-1 has also been shown to regulate insulin resistance, adipocyte differentiation, hepatic dysfunction and depression. However, the roles of BI-1 in these disease conditions are not fully consistent among studies. Until now, the molecular mechanisms of BI-1 have not directly explained with regard to how these conditions can be regulated. Therefore, this review investigates the physiological role of BI-1 through molecular mechanism studies and its application in various diseases.
Keywords: Bax inhibitor-1, ER stress, lysosome, reactive oxygen species, unfolded protein response.
Current Molecular Medicine
Title:The Characteristics of Bax Inhibitor-1 and its Related Diseases
Volume: 14 Issue: 5
Author(s): B. Li, R.K. Yadav, G.S. Jeong, H.-R. Kim and H.-J. Chae
Affiliation:
Keywords: Bax inhibitor-1, ER stress, lysosome, reactive oxygen species, unfolded protein response.
Abstract: Bax inhibitor-1 (BI-1) is an evolutionarily-conserved endoplasmic reticulum protein. The expression of BI-1 in mammalian cells suppresses apoptosis induced by Bax, a pro-apoptotic member of the Bcl-2 family. BI-1 has been shown to be associated with calcium (Ca2+) levels, reactive oxygen species (ROS) production, cytosolic acidification, and autophagy as well as endoplasmic reticulum stress signaling pathways. According to both in vitro and clinical studies, BI-1 promotes the characteristics of cancers. In other diseases, BI-1 has also been shown to regulate insulin resistance, adipocyte differentiation, hepatic dysfunction and depression. However, the roles of BI-1 in these disease conditions are not fully consistent among studies. Until now, the molecular mechanisms of BI-1 have not directly explained with regard to how these conditions can be regulated. Therefore, this review investigates the physiological role of BI-1 through molecular mechanism studies and its application in various diseases.
Export Options
About this article
Cite this article as:
Li B., Yadav R.K., Jeong G.S., Kim H.-R. and Chae H.-J., The Characteristics of Bax Inhibitor-1 and its Related Diseases, Current Molecular Medicine 2014; 14 (5) . https://dx.doi.org/10.2174/1566524014666140603101113
DOI https://dx.doi.org/10.2174/1566524014666140603101113 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pituitary Stem Cells Drop Their Mask
Current Stem Cell Research & Therapy Surviving Sepsis Campaign: A Project to Change Sepsis Trajectory
Endocrine, Metabolic & Immune Disorders - Drug Targets The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects
Current Medicinal Chemistry Recent Efforts to Develop Imaging Methods and β -Cell-Specific Contrast Agents for Non-Invasive in vivo Assessment of β-Cell Mass
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Immunological Modulation by Lidocaine-Epinephrine and Prilocaine- Felypressin on the Functions Related to Natural Immunity in Neutrophils and Macrophages
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Effects of Diabetes on Murine Lipoproteins and Vascular Disease
Current Drug Targets Diagnosis and Treatment of Unilateral Forms of Primary Aldosteronism
Current Hypertension Reviews In Utero Exposure to Phthalates and Fetal Development
Current Medicinal Chemistry Lead Optimization Resources in Drug Discovery for Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Tacrolimus Toxicity Reverses the Inhibitory Effects of Renin Angiotensin System Blockade on PAI-1 Expression in Cardiac Tissue
Current Enzyme Inhibition Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches
Endocrine, Metabolic & Immune Disorders - Drug Targets Hexosomes: A Novel Drug Delivery System
Current Drug Delivery Ultrasound Contrast Agents: Updated Data on Safety Profile
Current Pharmaceutical Design Complementary Role of Herbal Medicine and Exercise in Cardiovascular Disease Prevention and Management: A Review of Evidence
Current Pharmaceutical Design Global View on Alzheimer’s Disease and Diabetes Mellitus: Threats, Risks and Treatment Alzheimer’s Disease and Diabetes Mellitus
Current Alzheimer Research Relationship of High-Sensitivity C-Reactive Protein Concentrations and Systolic Heart Failure
Current Vascular Pharmacology HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Triamcinolone Acetonide and Bevacizumab Induced Raised Intraocular Pressure in An Elderly Male Diabetic Patient - A Case Report
Current Drug Safety Microscopies at the Nanoscale for Nano-Scale Drug Delivery Systems
Current Drug Targets The Role of Regulatory T Cells in Contact Hypersensitivity
Recent Patents on Inflammation & Allergy Drug Discovery